ErbB1-ErbB4 nuclear and cytoplasmic overexpression, ethnicity and predicted outcome in prostate cancer

Targeted Oncology

Volumn 3, Issue 1, 2008, Pages 13-17

  Ben Yosef, R ^a   Sarid, D ^a   Vexler, A ^a   Lidawi, G ^a   Barnea, I ^a   Marmor, S ^a   Stavesky, A ^a   Starr, A ^a   Hachoshen, N Yaal ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

ErbB; Ethnicity; Immuno histo chemistry staining; Prognosis; Prostate

Indexed keywords

EID: 38349118806     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-007-0069-y     Document Type: Article

References (22)

1. Barton J, Blackledge G, Wakeling A et al (2001) Growth factors and their receptors: new targets for prostate cancer therapy. Urology 58:114-122
2. Di Lorenzo G, Tortora G, D'Armiento FP et al (2002) Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 8:3438-3444
3. Gil-Diez de Medina S, Salomon L, Colombel M et al (1998) Modulation of cytokeratin subtype, EGF receptor, and androgen receptor expression during progression of prostate cancer. Hum Pathol 29:1005-1012
4. Moul JW, Maygarden SJ, Ware JL et al (1996) Cathepsin D and epidermal growth factor receptor immunohistochemistry does not predict recurrence of prostate cancer in patients undergoing radical prostatectomy. J Urol 155:982-985
5. Scher HI, Sarkis A, Reuter V et al (1995) Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. Clin Cancer Res 1:545-550
6. Mellon K, Thompson S, Charlton RG et al (1992) p53,c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. J Urol 147:496-499
7. Kuhn EJ, Kurnot RA, Sesterhenn IA et al (1993) Expression of the c-erbB-2 (HER-2/neu)oncoprotein in human prostatic carcinoma. J Urol 150:1427-1433
8. Fossa A, Lilleby W, Fossa SD et al (2002) Independent prognostic significance of HER-2 oncoprotein expression in pN0 prostate cancer undergoing curative radiotherapy. Int J Cancer 99:100-105
9. Osman I, Scher HI, Drobnjak M et al (2001) HER-2/neu (p185neu)protein expression in the natural or treated history of prostate cancer. Clin Cancer Res 7:2643-2647
10. Reese DM, Small EJ, Magrane G et al (2001) HER2 protein expression and gene amplification in androgen-independent prostate cancer. Am J Clin Pathol 116:234-239
11. Signoretti S, Montironi R, Manola J et al (2002) Her-2-neu expression and progression toward androgen independence inhuman prostate cancer. J Natl Cancer Inst 92:1918-1925
12. Savinainen KJ, Saramaki OR, Linja MJ et al (2002) Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. Am J Pathol 160:339-445
13. Hernes E, Fossa SD, Berner AA et al (2004) Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen independence. Br J Cancer 90:449-454
14. Ni CY, Murphy MP, Golde TE et al (2001) Gamma-secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 294:2179-2181
15. Lo HW, Xia W, Wei Y et al (2005) Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res 65:338-348
16. Rebbeck TR (2005). Genetics, disparities, and prostate cancer. LDI Issue Brief 10:1. http://www.upenn.edu/ldi/issuebrief10_7.pdf. Accessed 19 Nov 2007
17. Whittemore AS, Cirillo PM, Feldman D et al (2005) Prostate-specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of Black and White Americans. J Urol 174:872-876
18. Kattan MW, Zelefsky MJ, Kupelian PA et al (2003) Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer. J Clin Oncol 21:4568-4571
19. Canil CM, Moore MJ, Winquist E et al (2005) Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 23:455-460
20. Ziada A, Barqawi A, Glode LM et al (2004) The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate 60:332-337
21. Lara PN Jr, Chee KG, Longmate J et al (2004) Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer 100:2125-2131
22. Ben-Yosef R, Starr A, Karaush V et al (2007) ErbB-4 may control behavior of prostate cancer cells and serve as a target for molecular therapy. Prostate 67:871-880